SMNR (Semnur Pharmaceuticals) Moat Score: 3/10 (As of Jul. 09, 2026)


SMNR Semnur Pharmaceuticals Inc SMNR
8 GF Score
Price $0.71
View Full Analysis

What is Semnur Pharmaceuticals Moat Score?

Semnur Pharmaceuticals SMNR +9.23% 8 Moat Score is 3 as of Jul. 09, 2026. GuruFocus rates SMNR with a GF Score™ of 8/100. Among 1,394 Biotechnology companies, Semnur Pharmaceuticals ranks better than 75.54% on this metric.

Semnur Pharmaceuticals has the Moat Score of 3, which implies that the company might have No Moat - Very weak/transient advantages.

Semnur Pharmaceuticals has No Moat: Semnur Pharmaceuticals has limited market presence and lacks significant intellectual property or regulatory barriers. Its competitive advantages are weak and transient, with no strong brand or customer loyalty.

Moat Score is a ranking system developed by GuruFocus to assess a company's ability to sustain a competitive advantage, rated on a scale from 0 to 10. It takes into account key factors such as market leadership, cost advantages, network effects, customer switching costs, and more.

The company's Moat Score is based on these criteria:

1. Market leadership and sustainable market share
2. Network effects and significant customer switching costs
3. Valuable intellectual property and patents
4. Strong brand strength and deep customer loyalty
5. Durable cost advantages (e.g., economies of scale, proprietary technology)
6. Significant regulatory barriers and exclusive licenses
7. Superior distribution network
8. Strong and sustainable pricing power
9. Consistent and impactful innovation and R&D capabilities

Based on the research, GuruFocus believes Semnur Pharmaceuticals might have No Moat - Very weak/transient advantages.

Semnur Pharmaceuticals  (OTCPK:SMNR) Moat Score Explanation

The Moat Score ranges from 0 to 10, with 10 as the highest. GuruFocus divided Moat Score into following 8 categories:

Moat Score Moat Level
10Wide Moat - Exceptionally dominant and durable wide moat
8 - 9Wide Moat - Clear and robust wide moat
7Wide Moat - Entry-level wide moat, clearly possessing durable advantages
6Narrow Moat - Strong narrow moat, clearly distinguishable but not wide
5Narrow Moat - Solid narrow moat
4Narrow Moat - Discernible but modest moat
1 - 3No Moat - Very weak/transient advantages
0No Moat - No discernible moat

Semnur Pharmaceuticals Moat Score Related Terms

SMNR vs CNTB, ENLV, MENS: Moat Score Comparison

For the Biotechnology subindustry, Semnur Pharmaceuticals's Moat Score, along with its competitors' market caps and Moat Score data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Semnur Pharmaceuticals Moat Score vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Semnur Pharmaceuticals's Moat Score distribution charts can be found below:

* The bar in red indicates where Semnur Pharmaceuticals's Moat Score falls into.


SMNR
8GF Score
Semnur Pharmaceuticals Inc SMNR
Moat Score is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis
Frequently Asked Questions Learn more about Moat Score →
What does a Moat Score of 3 mean?
Semnur Pharmaceuticals (SMNR) has a Moat Score of 3 as of Jul. 09, 2026. Moat Score is a ranking system developed by GuruFocus to assess a company's ability to sustain a competitive advantage, rated on a scale from 0 to 10. It takes into account key factors such as market leadership, cost advantages, network effects, customer switching costs, and more. According to the industry distribution chart, Semnur Pharmaceuticals ranks #341 out of 1394 companies in the Biotechnology industry, placing it in the top 24.5%.
Is Semnur Pharmaceuticals' Moat Score too high?
Semnur Pharmaceuticals' current Moat Score is 3. The Biotechnology industry median Moat Score is 2.00. Semnur Pharmaceuticals' value of 3 is 50% above this industry median. Based on the distribution chart, Semnur Pharmaceuticals ranks #341 out of 1394 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers. Overall, Semnur Pharmaceuticals has a GF Score™ of 8/100, reflecting its overall financial health beyond just this single metric.
How does Semnur Pharmaceuticals' Moat Score compare to CNTB and ENLV?
According to the Biotechnology industry distribution chart, Semnur Pharmaceuticals ranks #341 out of 1394 companies for Moat Score. This places Semnur Pharmaceuticals in the top 25% of its industry — outperforming the majority of peers. The industry median Moat Score is 2.00. Semnur Pharmaceuticals' value of 3 is 50% above this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Moat Score for a Biotechnology company?
The median Moat Score among Biotechnology companies is 2.00, based on 1,394 companies in the industry. Companies in the top quartile (top 25%) have a Moat Score significantly above this median, while those in the bottom quartile fall well below. However, Moat Score should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Semnur Pharmaceuticals's current Moat Score of 3 is 50% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Moat Score mean?
A high Moat Score can signal that a stock is expensive relative to its fundamentals. Moat Score is a ranking system developed by GuruFocus to assess a company's ability to sustain a competitive advantage, rated on a scale from 0 to 10. It takes into account key factors such as market leadership, cost advantages, network effects, customer switching costs, and more. For the Biotechnology industry, the median Moat Score is 2.00 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Semnur Pharmaceuticals's current Moat Score is 3. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Semnur Pharmaceuticals stock overvalued right now?
Semnur Pharmaceuticals (SMNR) has a current Moat Score of 3. The current Moat Score is 3 and 50% above the Biotechnology industry median of 2.00. Semnur Pharmaceuticals' overall GF Score™ is 8/100. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Moat Score calculated?
Moat Score is calculated from a company's financial statements. For Semnur Pharmaceuticals (SMNR), the current Moat Score is 3 as of Jul. 09, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Semnur Pharmaceuticals Business Description

Address 960 San Antonio Road, Palo Alto, CA, USA, 94303
Semnur Pharmaceuticals Inc is a late-stage clinical biopharmaceutical company focused on developing and commercializing non-opioid pain management products for the treatment of acute and chronic pain. Its main product candidate, SP-102 (10 mg, dexamethasone sodium phosphate viscous gel), is being developed as a non-opioid novel injectable corticosteroid gel formulation for patients with moderate to severe LRP (also known as sciatica), containing no preservatives, surfactants, solvents, or particulates.
8GF Score

Get the complete analysis for SMNR

Moat Score is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$0.71
Price